2nd Annual MarketsandMarkets

ImmunoBio Series

14th - 15th October 2024

Dorint Thermenhotel- Gesundheitsresort Freiburg

Introducing the 2nd Annual MarketsandMarkets ImmunoBio Series, a groundbreaking event uniting the realms of Biomarker and Immuno-Oncology, set to unfold on 14th - 15th October 2024 in Dorint Thermenhotel- Gesundheitsresort Freiburg.

Dive deep into the convergence of biomarkers and immuno-oncology at our flagship conference, where industry pioneers, thought leaders, and experts converge to drive innovation in healthcare and biotechnology. This transformative event offers a dynamic platform for collaboration, knowledge exchange, and exploration of cutting-edge research and applications in personalized medicine and cancer treatment.

Esteemed keynote speakers will deliver groundbreaking insights into the latest developments and prospects of biomarker research and immuno-oncology, setting the stage for impactful discussions and networking opportunities. With over 40 speakers from leading pharma, biopharma, and biotech companies worldwide, attendees will gain invaluable insights into the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors, and Cellular Therapy, shaping the future of immuno-oncology.

Experience immersive sessions, brainstorming panel discussions, and case studies that delve into the challenges and solutions in biomarker and immuno-oncology research and development. From oncology to non-oncology indications such as Alzheimer’s and Parkinson’s, discover the latest advancements revolutionizing personalized medicine pipelines.

Explore the frontier of healthcare innovation and collaboration at the 2nd Annual MarketsandMarkets ImmunoBio Series, where innovation meets collaboration to shape the future of healthcare and biotechnology. Join us for this transformative event and make a marked difference in patient outcomes.

WHAT TO EXPECT

  1. Preclinical and Translational Immuno-Oncology Developments
  2. Biomarker Discovery Techniques: Explore novel strategies, including genomics, proteomics, metabolomics, and bioinformatics, to identify cutting-edge biomarkers in oncology.
  3. Precision Medicine Tailoring: Understand the pivotal role of biomarkers in customizing immunotherapy for individual patients, enhancing efficacy, and minimizing side effects.
  4. Personalizing Cancer Treatment- Challenges and Opportunities
  5. Rigorous Biomarker Validation: Learn strategies and overcome challenges in validating biomarkers for clinical use, ensuring robust and reliable results.
  6. Bioinformatics and AI Analysis: Attend sessions on biomarker data analysis, employing machine learning and artificial intelligence approaches for comprehensive insights.
  7. Biomarker-Based Cancer Diagnostics Development: Gain insights into the development and commercialization of diagnostic tests and platforms based on biomarkers.
  8. Next Gen Antibodies and Targeted Therapies
  9. Immune Checkpoint Inhibitors and Combination Therapies
  10. Tumor Microenvironment and Cancer Biomarkers
  11. CAR-T cell therapy, T Cell Therapy, Adoptive Cell Therapy
  12. Cancer Vaccines and Cancer Microbiome
  13. Collaboration for Advancement: Explore sessions on fostering collaboration among academia, industry, and government agencies to drive biomarker research forward.

  1. Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer and immunology.
  2. Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
  3. Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
  4. Professional Development: Enhance your skills with workshops on cancer biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
  5. Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
  6. Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.

Engage in groundbreaking research, expand your network, and drive innovation at the Immunobio Series, where science meets collaboration.

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Philip Arlen

Philip Arlen, MD, President and CEO, Precision Biologics, Inc

08:55 - 09:00

REDEFINING CANCER IMMUNOTHERAPY: FROM TUMOR MICROENVIRONMENT MODULATION TO IMMUNOGENIC THERAPIES AND BIOMARKER INNOVATIONS

Keynote Presentation - Unveiling Tumor Microenvironment Resistance Targets with the iOTarg Screening Platform - Featuring IOMX-0675, a LILRB1 and LILRB2 Cross-Specific Dual-Targeting Antibody

Adriana Turqueti Neves

Adriana Turqueti Neves, Associate Director, iOmx Therapeutics AG

09:00 - 09:30

Proteome Sciences

09:30 - 10:00

Novel drug-resistant mouse models for Immuno-Oncology research

Jianming Xu

Jianming Xu, Director, InVivo Pharmacology, GemPharmatech

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

HLA-I and HLA-II Immunopeptidome Profiling and its use in Studies from Discovery to Clinic

Anamarija Pfeiffer

Anamarija Pfeiffer, Senior Scientific Project Manager, Biognosys

11:15 - 11:45

Targeting Dendritic Cells to make Cancer Cell Death Immunogenic

Raj Mehta

Raj Mehta, Chief Executive Officer, Adendra Therapeutics Ltd

11:45 - 12:15

Arenavirus-based immuno-virotherapy: efficacious anti-tumor activity combined with advantageous effects on the tumor microenvironment (TME)

Sarah-Kim Friedrich-Becker

Sarah-Kim Friedrich-Becker, Senior Principal Scientist, Abalos Therapeutics GmbH

12:15 - 12:45

Challenges and opportunities for digital biomarkers from histopathology (IHCs)

Philipp Wortmann

Philipp Wortmann, Director, Translational Science, Astrazeneca

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

UNVEILING PROGRESS IN IMMUNE CHECKPOINTS, QTCR PLATFORMS, AND CAR T-CELL STRATEGIES

Immune checkpoint inhibitors: insights and advances from CRO perspective

Holger Weber

Holger Weber, Head of In Vivo Pharmacology, Reaction Biology Europe GmbH

14:15 - 14:45

Seqalis’ qTCR seq platform, an unbiased and quantitative enabling platform to unlock the immune repertoire diversity

Jean-Luc Henrioul

Jean-Luc Henrioul, Chief Operating Officer, Seqalis

14:45 - 15:15

Leveraging a Novel Non-Gene Edited Platform to Improve Efficacy and Safety of CAR T-Cell Therapies

Marine Blackman

Marine Blackman, Research Scientist, Celyad Oncology

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)

Eric Halioua

Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA

16:30 - 17:00

Gene expression signatures to study tumor immunology: pitfalls and success factors

Eike Staub

Eike Staub, Head of Oncology Data Science, Merck Healthcare, Germany

17:00 - 17:30

Closing Remarks from the Chairperson

Philip Arlen

Philip Arlen, MD, President and CEO, Precision Biologics, Inc

17:30 - 17:35

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

Daniel Crowley

Daniel Crowley, CEO, RemedyBio

08:55 - 09:00

INNOVATIVE STRATEGIES IN IMMUNOTHERAPY AND BIOMARKERS DEVELOPMENT

Keynote Presentation - Neuropilin-1 (NRP1) as novel target for antisense oligonucleotides (ASOs) to treat patients with solid tumors

Frank Jaschinski

Frank Jaschinski, CSO, Secarna Pharmaceuticals

09:00 - 09:30

Translational Genomics: An Overview Of Different Sequencing Strategies In Using Single-Cell Data Analysis

Rick Kamps

Rick Kamps, NGS Manager, Maastricht University

09:30 - 10:00

Ultrasensitive ISP assays for high quality spatial insights.

Angela Vasaturo

Angela Vasaturo , Director of Scientific Affairs, Ultivue

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Deciphering immune function in cancer by mass-scale single cell biology

Daniel Crowley

Daniel Crowley, CEO, RemedyBio

11:15 - 11:45

Validation of melanoma non-responders fingerprint fit, to the mechanism of action JJP-1008.

Tomasz Grabowski

Tomasz Grabowski, Head of Preclinical Development, JJP Biologics

11:45 - 12:15

Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies

Philip Arlen

Philip Arlen, MD, President and CEO, Precision Biologics, Inc

12:15 - 12:45

Predicting Patient Response to Checkpoint Inhibitors

Jens Kringelum

Jens Kringelum, VP, AI & Innovation, Evaxion Biotech

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

LATEST DEVELOPMENTS & TRENDS IN IO & BIOMARKER RESEARCH

Resistance of cancer in the context of mAbs MOA. Is the next ICIs just a rabbit chase

Tomasz Grabowski

Tomasz Grabowski, Head of Preclinical Development, JJP Biologics

Jianming Xu

Jianming Xu, Director, InVivo Pharmacology, GemPharmatech

Adriana Turqueti Neves

Adriana Turqueti Neves, Associate Director, iOmx Therapeutics AG

Philip Arlen

Philip Arlen, MD, President and CEO, Precision Biologics, Inc

14:15 - 14:45

Closing Remarks from the Chairperson

14:45 - 14:45

SPEAKERS

Eike Staub

Eike Staub

Head of Oncology Data Science, Merck Healthcare, Germany

Jianming Xu

Jianming Xu

Director, InVivo Pharmacology, GemPharmatech

Philip Arlen

Philip Arlen

MD, President and CEO, Precision Biologics, Inc

Philipp Wortmann

Philipp Wortmann

Director, Translational Science, Astrazeneca

Marine Blackman

Marine Blackman

Research Scientist, Celyad Oncology

Anamarija Pfeiffer

Anamarija Pfeiffer

Senior Scientific Project Manager, Biognosys

Daniel Crowley

Daniel Crowley

CEO, RemedyBio

Jean-Luc Henrioul

Jean-Luc Henrioul

Chief Operating Officer, Seqalis

Frank Jaschinski

Frank Jaschinski

CSO, Secarna Pharmaceuticals

Raj Mehta

Raj Mehta

Chief Executive Officer, Adendra Therapeutics Ltd

Rick Kamps

Rick Kamps

NGS Manager, Maastricht University

Eric Halioua

Eric Halioua

President & Chief Executive Officer, PDC*line pharma SA

Sarah-Kim Friedrich-Becker

Sarah-Kim Friedrich-Becker

Senior Principal Scientist, Abalos Therapeutics GmbH

Adriana Turqueti Neves

Adriana Turqueti Neves

Associate Director, iOmx Therapeutics AG

Jens Kringelum

Jens Kringelum

VP, AI & Innovation, Evaxion Biotech

Holger Weber

Holger Weber

Head of In Vivo Pharmacology, Reaction Biology Europe GmbH

Tomasz Grabowski

Tomasz Grabowski

Head of Preclinical Development, JJP Biologics

Angela Vasaturo

Angela Vasaturo

Director of Scientific Affairs, Ultivue

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Dorint Thermenhotel- Gesundheitsresort Freiburg

PAST EVENT GALLERY